SCHEMBL30294647

SCHEMBL30294647

Cc1cc(F)ccc1Nc1cc(Cl)c(F)cc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLCN2 P51788 2/20 0.53
MAPK13 O15264 1/20 0.49
MAPK12 P53778 1/20 0.49
MAPK11 Q15759 1/20 0.49
MAPK14 Q16539 1/20 0.49
FABP3 P05413 2/20 0.49
FABP4 P15090 2/20 0.49
FTO Q9C0B1 2/20 0.47
IDO1 P14902 2/20 0.44
P2RY4 P51582 1/20 0.44
DHODH Q02127 2/20 0.41
MKNK2 Q9HBH9 1/20 0.41
AVPR2 P30518 1/20 0.41
OXTR P30559 1/20 0.41
AVPR1A P37288 1/20 0.41
STING1 Q86WV6 1/20 0.40
POLB P06746 1/20 0.40
MPO P05164 1/20 0.40
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30294669 0.95 CLCN2 (0.53) CLCN2MAPK13MAPK12MAPK11MAPK14
SCHEMBL22853082 0.95 CLCN2 (0.53) CLCN2MAPK13MAPK12MAPK11MAPK14
SCHEMBL22853083 0.89 MEN1 (0.51) CLCN2FABP3FABP4FTOIDO1
SCHEMBL22853121 0.89 IDO1 (0.48) CLCN2MAPK13MAPK12MAPK11MAPK14
SCHEMBL30294377 0.89 IDO1 (0.48) CLCN2MAPK13MAPK12MAPK11MAPK14
SCHEMBL22853346 0.87 IDO1 (0.50) CLCN2MAPK13MAPK12MAPK11MAPK14
SCHEMBL30294440 0.87 IDO1 (0.50) CLCN2MAPK13MAPK12MAPK11MAPK14
SCHEMBL22853383 0.84 P2RY4 (0.56) CLCN2MAPK13MAPK12MAPK11MAPK14
SCHEMBL30294653 0.84 P2RY4 (0.56) CLCN2MAPK13MAPK12MAPK11MAPK14
SCHEMBL22853462 0.84 CLCN2 (0.48) CLCN2MAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B CLCN2 192/4885MAPK13 3275/4885MAPK12 3283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.